(ख) फर्टिलाइजर कार्पोरेशन आफ इंडिया (एफ सी आई) की सिन्दरी इकाई की वार्षिक स्थापित क्षमता 219'000 टन नाइट्रोजन है।

एफ सी आई 16.23 करोड़ रुपए की लगत पर कैप्टिव पावर संयंत्र सहित सिन्दरी इकाई के पुनरूद्धार के चरण-I को पहले ही कार्यान्वित कर रहा है। एफ सी आई द्वारा सिन्दरी इकाई का दर्जा बढ़ाने के लिए तैयार की गयी अन्य योजनाओं को कम्पनी के पास निधियों के अभाव के कारण हाथ में नहीं लिया जा सका।

Pirces of Emflam adn Cmbiflam

2931. SHRIMATI KAILASHPATI:
SHRI SANTOSH KUMAR SAHU:

Will the PRIME MINISTER be pleased to state:

(a) what was the price declared by Government for Emflam Plus on 1.12.1988;

(b) what was the price declared by Government for Combiflam on 1.12.1988; and

(c) whether there is a price difference between the two, the reasons for such differentiation since both products fall under same category and have the same formulation?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) Rs. 5.10 for 10's strip.

(b) Rs. 4.90 for 10's strip.

(c) As per the records, difference in prices is due to variation in packing charges, material cost and excise duty.

Murthy Committee on Glaxo affairs

2932. SHRI RAJNI RANJAN SAHU:
SHRIMATI SATYA BAHIN:

Will the PRIME MINISTER be pleased to state:

(a) whether Government's attention has been drawn to a news item which appeared in Orissa Times dated 14th December, 1992 under the caption Murthy Committee on Glaxo affairs;

(b) whether it is a fact that this committee was set up to review the Supreme Court cases and not the High Court cases as per its terms of reference;

(c) the reasons for violating these terms of reference and the case of M/s. Glaxo was entrusted to this committee.

(d) what were the findings of the then additional Secretary and Financial Adviser on all these cases;

(e) whether it is also a fact that Government also decided to fix up the responsibility of all those who were involved in suppressing the liabilities;

(f) if so, the action taken thereon; and

(g) what is the present position?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) Yes Sir. The Government has seen the news item appeared in Orissa Times on 14-12-1992 under the Caption "Finance Ministry's liberal duty exemption to Glaxo".

(b) to (g) M/s. Glaxo had filed a Writ Petition in the Delhi High Court in 1981 against the Price fixation order of the Government of 12th

May, 1981 and the Delhi High Court gave judgement on 31st August, 1987 and gave direction to the Government to give hearing to the company and review the prices. The job to review the prices of Betamethasone and its salt was assigned for the sake of convenience to the Murthy Committee as this Committee was already engaged at this point of time in a similar task in the 12 companies involved in the Supreme Court. This case is now being finally heard in the Delhi High Court and the matter is therefore sub-judice.

Fall in consumption of drugs

2933. SHRIMATI SATYA BAHIN: Will the PRIME MINISTER be pleased to state:

(a) what are the reasons for decline in productien of Ranbaxy Labs. Ltd. bulk drugs produced from basic stages like Chlorampsenicol, Tetracycline Hcl, Ampicillin, Amoxicillin, Doxycycline, Gentamycin, Ranitidine, Cephalexin, Kenamycin, Sulphadiazine, Sulphamoxole and several other bulk drugs;

(b) whether it is a fact that exports of these drugs are finding their way back ino the country and also that records of imports of inputs, their utilisation and exports are being manipulated;

(c) whether the consumption of these drugs in the formulations has also fallen; if not, what steps Government have taken for consumption in formulations; and

(d) what are the details in this regard and what follow up action has been taken to investigate overcharging of prices of medicines from the consumer?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a), (c) and (d) To the extent data is available there is a decline in production of these drugs in the organised sector in 1991-92 as compared to that of the previous year. This declining trend is seen in the production figures of M/s. Ranbaxy Labs. also for drugs in their production range. The reasons for such reduction could be due to various factors such as change in demand pattern, enhanced production in the SSI Sector, corporate strategy, import compression measures, introduction of newer drugs etc. However, no shortages of these drugs have been reported. Whenever any instance of a company selling a formulation at a price higher than that fixed by the Government comes to notice, the matter is taken up with the company or state Drug Controller for clarification|necessary action.

(b) As regards the records for imports of inputs, their utilisation and exports, the Director General of Foreign Trade Organisation ensures that the specified quantities of imports and exports are in order.

Tinidazole being outside prices control

2934. SHRI RAJNI RANJAN SAHU: Will the PRIME MINISTER be pleased to state:

(a) what are the reasons for controlling price of Metronidazole and keeping Tinidazole outside price control;

(b) whether it is also a fact that cost of production of Tinidazole is less than the cost of production of Metronidazole but the formulations of the drugs are being sold at three times the price; and

(c) the reasons for such state of Affairs and what steps have been aken to look into the matter and bring down the price by bringing this drug under price control or otherwise?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) and (b) The list